Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TasqForce trial of tasquinimod in refractory or intolerant myelofibrosis
2024-511565-11-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tasquinimod in myelofibrosis (MF) (2 arms), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity and recommended phase 2 dose and SVR35 at week 32. Planned start Oct 2024; status: authorised.
02
Drugs
tasquinimod
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2024-511565-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511565-11-00.